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Linear motifs normally bind with only medium binding afﬁnity (Kd of 0.1–
10 mM) to shallow protein-interaction surfaces on their binding partners. The
crystallization of proteins in complex with linear motif-containing peptides is
often challenging because the energy gained upon crystal packing between
symmetry mates in the crystal may be on a par with the binding energy of the
protein–peptide complex. Furthermore, for extracellular signal-regulated kinase
2 (ERK2) the protein–peptide docking surface is comprised of a small
hydrophobic surface patch that is often engaged in the crystal packing of apo
ERK2 crystals. Here, a rational surface-engineering approach is presented that
involves mutating protein surface residues that are distant from the peptide-
binding ERK2 docking groove to alanines. These ERK2 surface mutations
decrease the chance of ‘unwanted’ crystal packing of ERK2 and the approach
led to the structure determination of ERK2 in complex with new docking
peptides. These ﬁndings highlight the importance of negative selection in crystal
engineering for weakly binding protein–peptide complexes.
1. Introduction
Linear motifs (LMs) are simple protein–protein interaction tools
which are generally less than 20 amino acids in length. They normally
bind with only medium binding afﬁnity (Kd of 0.1–10 mM) to
shallow protein-interaction surfaces on their binding partners
(Neduva & Russell, 2005). As these protein–peptide-type inter-
actions are becoming established as playing an equally important role
as classical protein–protein associations in promoting biologically
relevant binding events in the cell, there is great interest in
structurally mapping out linear motif-binding protein surfaces. The
Eukaryotic Linear Motif database contains thousands of occurrences
of LMs in various organisms (Gould et al., 2010) and it is estimated
that the human proteome may contain more than 10 000 LMs
(Petsalaki & Russell, 2008). The moderate binding afﬁnity of LM-
containing peptides can hinder successful crystallization of the
desired protein–peptide complex. Because linear motif-containing
peptides are often unstructured alone and the energy gained upon
crystal packing between symmetry mates may be on a par with the
binding energy of the complex, the bona ﬁde peptide-binding protein
surface may mediate crystal packing rather than physiological LM
binding.
Mitogen-activated protein kinase (MAPK)-binding linear motifs
bind to the MAPK docking groove and represent a functionally well
characterized linear binding-motif class (Garai et al., 2012). Crystal-
lization of docking-motif (D-motif) peptides with MAPKs may serve
as a paradigm for the challenges of protein–peptide crystallization in
general (Chang et al., 2002; Heo et al., 2004; Zhou et al., 2006; Liu et
al., 2006; ter Haar et al., 2007; Ma et al., 2010; Garai et al., 2012). These
short peptides are 7–17 amino acids in length; they are unstructured
without their binding partners and they bind to their cognate MAPKs
with binding afﬁnities of 1–10 mM (Garai et al., 2012). Previously, we
attempted the crystallization of three different MAPKs (ERK2, p38
and JNK1) with different linear D-motif-containing peptides to gain
structural insight into their MAPK binding speciﬁcity (Garai et al.,
2012). In this study, we describe our experiences in the crystallization
of ERK2–docking peptide complexes. We set out to crystallize the
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wild-type protein (ERK2 WT) with six different peptides (Garai et
al., 2012). Unfortunately, ERK2 readily crystallized in the apo form
and we only managed to grow protein–peptide cocrystals with the
docking peptide from MNK1 (pepMNK1), which is an ERK2
substrate. Analysis of crystal-packing contacts subsequently revealed
that the protein–peptide binding surface of ERK2 WT was blocked
by a symmetry-related kinase molecule in all apo crystals, while
ERK2–pepMNK1 crystals could ‘luckily’ form because this peptide
mediated a different type of crystal packing. The peptide was engaged
in crystal contacts with an ERK2 symmetry molecule (Supplementary
Fig. S11). Other peptides, however, could not mediate this unique
crystal packing as they differed in length and sequence. Therefore, we
decided to devise a strategy by which the trial-and-error nature of
ERK2–docking peptide cocrystallization projects could be rationally
alleviated.
2. Experimental procedures
ERK2 (UniProt ID P28482) was expressed in E. coli with an
N-terminal histidine tag, which was subsequently removed using TEV
protease. The protease cleavage leaves a glycine–serine dipeptide
N-terminal to the ﬁrst ERK2 residue. The expression and puriﬁcation
of ERK2 is described in further detail in Garai et al. (2012). Brieﬂy,
recombinant ERK2 was subjected to afﬁnity puriﬁcation on Ni-
Sepharose, cleaved using TEV protease and loaded onto a
RESOURCE Q ion-exchange column. The protein was eluted using
an NaCl gradient, concentrated to 10 mg ml1 and stored in buffer
(20 mM Tris, 50 mM NaCl, 10% glycerol, 2 mM -mercaptoethanol
pH 8) at 193 K. ERK2 surface mutations were introduced by the
QuikChange site-directed mutagenesis protocol and mutant proteins
were expressed and puriﬁed in the same way as wild-type ERK2.
All crystallization experiments were performed in standard sitting-
drop vapour-diffusion setups at 296 K. ERK2 (150–200 mM) was
crystallized using a twofold molar excess of chemically synthesized
docking peptides in the presence of 2 mM AMPPNP and MgCl2. All
peptides were synthesized on an ABI 431A peptide synthesizer using
the Fmoc strategy.
For each ERK2–docking peptide complex we used an in-house
96-condition PEG-based grid screen. This screen consisted of only
low ionic strength (less than 200 mM salt) conditions, in which the pH
and molecular weight of the PEGs were systematically varied from
pH 5.5 to 8.5 and from PEG 200 to PEG 20 000, respectively. In
addition, we also used low ionic strength commercial sparse-matrix
screens (The PEGs and PEGs II Suites from Qiagen) for the initial
crystallization trials of all complexes.
All crystals were ﬂash-cooled after adding 15% glycerol to the
mother liquor as a cryoprotectant. Crystals were tested on a Rigaku
R200 rotating-anode X-ray generator at the Institute of Chemistry,
Eo¨tvo¨s Lora´nd University and diffraction data sets were collected on
the PXI or PXIII beamlines of the Swiss Light Source, Villigen,
Switzerland. All data were processed with XDS (Kabsch, 2010). The
phase problem was solved by molecular replacement with Phaser
(McCoy et al., 2007) using PDB entry 2gph (Zhou et al., 2006) as a
starting model. Structure reﬁnement was carried out using PHENIX
(Adams et al., 2010) and structure remodelling and building was
performed in Coot (Emsley et al., 2010) (Table 1).
3. Results
MKK2 is one of the upstream activator kinases of ERK2 that binds its
MAPK substrate with a linear docking motif (Garai et al., 2012). In
order to explore the structural basis of this interaction, we attempted
to crystallize ERK2 with a docking peptide fromMKK2 (pepMKK2).
Single crystals grew in 20–25%(w/v) PEG 6000 buffered with 0.1M
MIB (a composite buffer comprised of malonate, imidazole and boric
acid) pH 6.5. However, structure solution subsequently revealed that
these crystals did not contain the chemically synthesized peptide: the
MAPK docking groove was occupied by a crystallographic symmetry-
related kinase molecule. In order to devise a strategy to prevent this
kind of crystal packing in which the docking groove is blocked by a
symmetry mate, we ﬁrst analyzed the packing interactions of apo
ERK2 and the ERK2–pepMNK1 protein–peptide complex using
PISA (Krissinel & Henrick, 2007). Comparison of the main crystal
contacts observed in these two ERK2 structures revealed that Arg77
and Glu317 make two prominent hydrogen-bond-mediated contacts
with symmetry mates in the apo form, while these are not engaged in
the packing of the ERK2–pepMNK1 complex (Fig. 1a). Therefore,
we replaced these residues by alanines (ERK2_AA) to ‘weaken’ the
contacts in the crystal with a symmetry mate occupying the MAPK
docking groove.
Crystals grew readily in 20–25%(w/v) PEG 6000 buffered with
0.1M MIB pH 5.5 using this new ERK2 construct in the presence of
pepMKK2, but structure solution subsequently showed that these
crystals were of apo ERK2_AA (Table 2). We noticed that in both
types of apo structure (ERK2 WT and ERK2_AA) the side chain of
Ile255 of a symmetry-related MAPK molecule occupied one of the
important linear motif-binding hydrophobic pockets of the MAPK
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Table 1
Crystallographic data-collection and reﬁnement statistics for ERK2–docking
peptide complexes.
Values in parentheses are for the highest resolution shell.
ERK2_AA–pepRSK1_SQAA ERK2_AAGS–pepMKK2
Data collection
Space group P1 P212121
Unit-cell parameters
(A˚, )
a = 41.5, b = 58.8,
c = 79.2,  = 100.9,
 = 99.0,  = 90.0
a = 41.8, b = 58.5,
c = 159.2,
 =  =  = 90.0
Resolution (A˚) 42.37–2.3 (2.382–2.300) 47.15–2.2 (2.279–2.200)
Rmerge† 0.048 (0.322) 0.056 (0.611)
hI/(I)i 11.15 (2.43) 14.14 (2.25)
Completeness (%) 94.95 (93.31) 99.03 (96.49)
Multiplicity 1.8 (1.8) 3.3 (3.3)
Reﬁnement






Average B factors (A˚2)
Wilson B factor 35.1 41.7
Macromolecules 45.0 59.5
Solvent 38.8 44.2
R.m.s. deviations from ideal values
Bond lengths (A˚) 0.009 0.010
Bond angles () 1.35 1.41
Ramachandran analysis§, residues in (%)
Favoured regions 87.5 86.6
Allowed regions 12.2 13.1
Disallowed regions 0.3 0.3
















hkl jFobsj, where Fobs and Fcalc are the observed and calculated native structure factors,
repectively. Rfree is the same as Rwork but calculated using 5% of the total reﬂections which were
chosen randomly and omitted from the reﬁnement. § Ramachandran analysis was carried out
using PROCHECK (Laskowski et al., 1993).
1 Supplementary material has been deposited in the IUCr electronic archive
(Reference: BW5412). Services for accessing this material are described at the
back of the journal.
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docking groove (Fig. 1b). We decided to
directly mutate the contact residue (Ile255)
to glycine (ERK2_AAG) to make this type
of crystal packing less probable. Using the
ERK2_AAG construct, we could grow small
crystals in 25–30%(w/v) PEG 3000 buffered
with 0.1M Tris pH 8.5. The size of these
crystals was then increased by macroseeding.
Unfortunately, these crystals contained apo
ERK2_AAG; however, the space group and
packing were different compared with
previous apo ERK2 structures. Although the
packing of the apo ERK2_AAG crystals was
compatible with peptide binding because
the docking groove was ‘open’, Cys161 in
the MAPK docking groove made a
(2-hydroxyethyl)thiocysteine adduct with
-mercaptoethanol that was added to avoid
oxidation during macroseeding (Fig. 1c).
This modiﬁcation of Cys161 was likely to
occur during the longer time period required
for macroseeding crystallization experi-
ments and interfered with docking-peptide
binding. Oxidation of the corresponding
residue (Cys162) during the crystallization
of p38 MAPK has been observed
previously (Patel et al., 2004). We introduced
a cysteine-to-serine mutation into the
ERK2-AAG construct (ERK2_AAGS)
and used this for crystallization. The
ERK2_AAGS-pepMKK2 crystals ﬁnally
contained the peptide and diffracted to
2.2 A˚ resolution (Figs. 1d and 1e).
Parallel to our trials with pepMKK2, we
attempted to crystallize ERK2 with two
other peptides (pepRSK1 and pepRSK1_
SQAA). PepRSK1 contains a reverse
D-motif from a downstream MAP kinase-
activated protein kinase (MAPKAP) that is
a known ERK2 substrate (RSK1; Garai et
al., 2012). PepRSK1_SQAA is a mutated
version of pepRSK1 in which intra-peptide
hydrogen-bond stapling interactions were
removed by replacing a serine and a gluta-
mine residue by alanines (Garai et al., 2012).
In order to grow complex crystals with RSK1
peptides, we used the same sparse-matrix
short communications
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Table 2
Different apo ERK2 crystals and ERK2–docking peptide complexes.
The binding afﬁnity of peptides to ERK2 are from Garai et al. (2012); amino acids in consensus sequence positions are shown in bold.
Unit-cell parameters







ERK2 WT Apo 44.9 65.3 116.7 90.0 90.0 90.0 P212121 1.55 — —
ERK2_AA Apo 44.7 71.5 121.1 90.0 90.0 90.0 P212121 1.90 — —
ERK2_AAG Apo 86.5 86.5 311.1 90.0 90.0 120.0 H32 2.50 — —
ERK2 WT† MNK1 65.4 65.9 95.0 90.0 90.0 90.0 P212121 1.55 MKLSPPSKSRLAQRRALA 0.7
ERK2_AA† RSK1 41.7 59.0 155.7 90.0 90.0 90.0 P212121 2.40 PQLKPIESSILAQRRVRKLSPTTL 0.3
ERK2_AA RSK1_SQAA 41.5 58.8 79.2 100.9 90.0 90.0 P1 2.30 PQLKPIEASILAARRVRKLSPTTL 2
ERK2_AAGS MKK2 41.8 58.5 159.2 90.0 90.0 90.0 P212121 2.20 RRKPVLPALTINP 8
† These ERK2–docking peptide complexes were reported in Garai et al. (2012).
Figure 1
Surface engineering of ERK2 to interfere with ‘undesired’ crystal packing. (a) Arg77 forms hydrogen bonds with
Asn47 from a symmetry mate in the crystal (left panel) and Glu314 interacts with Gln119 and with Asn297 from
two ERK2 WT molecules (right panel). (b) The side chain of Ile255 from an ERK2 symmetry mate (coloured
teal) occupies the hydrophobic groove in the apo ERK2_AA structures. The superimposed ERK–pepDCC
complex structure (PDB entry 3o71; Ma et al., 2010), shown in dark grey (MAPK) and black (pepDCC), on
ERK2_AA demonstrates that this type of crystal packing is incompatible with D-motif peptide binding. (c) The
2Fo  Fc electron-density map contoured at 1 for the ﬁnal apo ERK2_AAG structure shows strong and
continuous density for the side chain of Cys161. This indicates adduct formation with -mercaptoethanol at this
cysteine residue. (d) Fo Fc simulated-annealing OMIT map contoured at 2 for the ERK2–pepMKK2 complex.
(e) Crystal structure of the ERK2–pepMKK2 complex. The ERK2 surface is coloured according to its
electrostatic potential (red, negative; blue, positive).
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screens that were also used for pepMNK1 and pepMKK2. However,
apo ERK2 crystals were always obtained when wild-type ERK2 was
used. Finally, we obtained complex crystals without the need for
macroseeeding by using the ERK2_AA construct in the presence of
pepRSK1 or pepRSK1_SQAA [in 25–30%(w/v) PEG 6000 buffered
with 0.1M MES pH 6.5; Table 2 and Supplementary Fig. S2].
4. Discussion
In summary, we were successful in interfering with the prevalent
crystal packing of ERK2 observed in many apo structures. Our goal
was to disfavour crystal packing in which the ERK2 peptide-binding
surface is blocked by a symmetry molecule (‘closed’) and to promote
new crystal packing in which the peptide-binding surface is ‘open’.
Surface mutations allowed ERK2 to crystallize with diverse packings
and some of them were compatible with docking-peptide binding.
These new packing arrangements were indeed more ‘relaxed’, as
expected, and this seemed to increase the chance of growing protein–
peptide cocrystals. In addition, the bound peptides (e.g. pepMKK2,
pepRSK1 and pepRSK1_QAA) were not involved in crystal packing
in the new cocrystals. For ﬂexible linear motifs this is more favourable
in order to capture them in their physiologically relevant binding
geometry.
Currently, examples of crystal engineering to increase the crystal-
lizability of protein constructs or to make poor-quality crystals
diffract better are more abundant in the literature compared with
examples involving negative selection against ‘unwanted’ crystal-
packing interactions (Heinz & Matthews, 1993; Lawson et al., 1991;
Yamada et al., 2007; Honjo et al., 2008). It was found for aspartyl-
tRNA synthetase that disruption of lattice contacts hinders crystal-
lization and that the addition of contacts favours it (Charron et al.,
2002). However, removing lattice contacts may produce crystals with
better diffraction resolution limits or may resolve twinning problems
(Green et al., 2001; Shimamura et al., 2009). There are several
methods of increasing the chance of crystallization for proteins if
sparse-matrix screens fail (Derewenda, 2010). These involve changing
the length of the protein construct or introducing chemical modiﬁ-
cations on surface residues (Dale et al., 2003; Walter et al., 2006). For
example, Zhou et al. (2006) covalently attached a docking peptide to
ERK2 by concurrently introducing cysteines into the peptide and
ERK2. An artiﬁcial disulﬁde bridge formed during crystallization
that ensured docking-peptide binding; however, this artiﬁcial cova-
lent bridge distorted the geometry of peptide binding in the MAPK
docking groove. These trial-and-error strategies may be contrasted
with a more rational approach: the surface-entropy reduction (SER)
method, which is based on replacing small clusters of two to three
surface residues characterized by high conformational entropy with
alanines (Derewenda & Vekilov, 2006). Furthermore, disruption of
known common crystal contacts may also be part of complex crystal-
engineering efforts, as reported for HIV-1 reverse transcriptase and
diphthine synthase (Bauman et al., 2008; Mizutani et al., 2008).
‘Unwanted’ crystal contacts may also hamper the crystallization of
larger protein–protein complexes. Selmer et al. (2012) had difﬁculties
in crystallizing the 70S ribosome in complex with the EF-G transla-
tional factor because the ribosomal L9 protein from a symmetry mate
in the crystal blocked the area responsible for EF-G binding. The
problem was solved by expressing and crystallizing ribosomes
without the L9 ribosomal protein; these readily crystallized in
complex with different translational factors. It is acknowledged that
the idea of a surface-engineering-based approach involving negative
selection against speciﬁc lattice contacts is not new (Charron et al.,
2002; Green et al., 2001; Shimamura et al., 2009); however, we are not
aware of other studies in which this has been exploited for difﬁcult
protein–peptide crystallization problems. We believe that a more
widespread application of similar rational approaches to those
described for ERK2 in this study could be a great asset in tackling
other difﬁcult protein–peptide complex crystallization projects,
particularly where the protein–peptide interface shows a propensity
for mediating ‘unwanted’ crystal packing.
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